Table 3.
Association between ursodeoxycholic acid (UDCA) treatment and metachronous adenoma, stratified by sex and age
| Age (tertiles), y | Men |
Women |
||||
|---|---|---|---|---|---|---|
| 40 – 64 (n = 276) |
65 – 71 (n = 291) |
72 – 81 (n = 237) |
40 – 64 (n = 142) |
65 – 71 (n = 126) |
72 – 81 (n = 120) |
|
|
|
|
|||||
| Any adenoma | ||||||
| UDCA, n (%) | 58/147 (39) | 65/158 (41) | 59/118 (50) | 23/71 (32) | 25/60 (42) | 21/59 (36) |
| Placebo, n (%) | 57/129 (44) | 59/133 (44) | 63/119 (53) | 25/71 (35) | 20/66 (30) | 30/61 (49) |
| OR (95% CI) | 0.82 (0.51 – 1.33) | 0.88 (0.55 – 1.40) Pinteraction* = 0.318 (0.973) |
0.89 (0.53 – 1.48) | 0.88 (0.44 – 1.77) | 1.64 (0.79 – 3.42) Pinteraction = 0.362 (0.131) |
0.57 (0.27 – 1.19) |
| Advanced lesion† | ||||||
| UDCA, n (%) | 20/146 (14) | 25/155 (16) | 17/117 (15) | 14/71 (20) | 11/59 (19) | 12/59 (20) |
| Placebo, n (%) | 26/129 (20) | 28/133 (21) | 29/117 (5) | 5/71 (7) | 9/66 (14) | 13/60 (22) |
| OR (95% CI) | 0.63 (0.33 – 1.19) | 0.72 (0.40 – 1.31) Pinteraction = 0.466 (0.762) |
0.52 (0.27 – 1.00) | 3.24 (1.10 – 9.56) | 1.45 (0.56 – 3.79) Pinteraction = 0.015 (0.194) |
0.92 (0.38 – 2.23) |
| Proximal location‡ | ||||||
| UDCA, n (%) | 34/145 (23) | 54/158 (34) | 45/117 (38) | 15/71 (21) | 19/60 (32) | 16/59 (27) |
| Placebo, n (%) | 43/128 (34) | 43/133 (32) | 46/119 (39) | 16/71 (23) | 15/66 (23) | 23/61 (38) |
| OR (95% CI) | 0.61 (0.36 – 1.03) | 1.09 (0.67 – 1.77) Pinteraction = 0.773 (0.243) |
0.99 (0.59 – 1.68) | 0.92 (0.42 – 2.04) | 1.58 (0.71 – 3.48) Pinteraction = 0.438 (0.245) |
0.61 (0.28 – 1.33) |
| Multiple adenomas§ | ||||||
| UDCA, n (%) | 8/147 (5) | 17/158 (11) | 16/118 (14) | 3/71 (4) | 1/60 (2) | 3/59 (5) |
| Placebo, n (%) | 10/129 (8) | 16/133 (12) | 14/119 (12) | 3/71 (4) | 3/66 (5) | 8/61 (13) |
| OR (95% CI) | 0.68 (0.26 – 1.79) | 0.88 (0.43 – 1.82) Pinteraction = 0.888 (0.679) |
1.18 (0.55 – 2.53) | 1.00 (0.19 – 5.13) | 0.36 (0.04 – 3.52) Pinteraction = 0.264 (0.602) |
0.35 (0.09 – 1.41) |
Abbreviations: UDCA, ursodeoxycholic acid; OR, odds ratio; CI, confidence interval
*
P for treatment-by-age interaction calculated using likelihood ratio tests with continuous (and categorical) age
†
Advanced: adenocarcinoma, high-grade dysplasia, villous or tubulovillous histology, or large (≤ 1 cm); missing advanced lesion data for 7 men and 2 women
‡
Proximal: any proximal adenoma; missing proximal location data for 4 men and 0 women
§
Multiple: three or more adenomas